Clinical Trials
18 trialsNCT05182957 2026-05-01
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 2 Recruiting
NCT04261439 2025-05-06
A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab
Novartis
Phase 1 Terminated
NCT06758037 2025-03-18
HiR+X
First Affiliated Hospital of Ningbo University
Phase 2 Recruiting
NCT03058289 2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2 Completed
NCT05631886 2023-08-28
Combination of CAR-DC Vaccine and ICIs in Malignant Tumors
Chinese PLA General Hospital
Phase 1 Recruiting
NCT03311412 2023-05-30
Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
Phase 1 Completed
NCT05821192 2023-04-20
Chemotherapy Plus PD-1 Monoclonal Antibody in the Treatment of Refractory or Relapsed Peripheral T-cell Lymphoma.
The First Hospital of Jilin University
Phase NA Unknown
NCT03365791 2022-05-27
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Novartis
Phase 2 Completed
NCT03172936 2022-05-03
Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Novartis
Phase 1 Terminated
NCT05254899 2022-02-24
Anti-PD-1 Antibody and P-GEMOX Chemotherapy Combined With Radiotherapy in High-risk Early-Stage ENKTL
ChineseAMS
Phase 2 Unknown
NCT05149170 2021-12-08
Radiotherapy and Anti-PD-1 in Low-risk ES-ENKTCL
ChineseAMS
Phase 2 Unknown
NCT02677155 2021-03-01
Lymvac-2
Oslo University Hospital
Phase 2 Completed
NCT02740270 2021-02-21
Phase I/Ib Study of GWN323 Alone and in Combination With PDR001 in Patients With Advanced Malignancies and Lymphomas
Novartis
Phase 1 Completed
NCT04676789 2020-12-21
SPENT
Sun Yat-sen University
Phase 2 Unknown
NCT04279379 2020-05-07
Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma
Beijing Tongren Hospital
Phase 2 Unknown
NCT04338282 2020-04-08
Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma
Beijing Tongren Hospital
Phase 2 Unknown
NCT04096690 2020-03-11
Anti-PD-1 Antibody Combined With Pegaspargase in the Treatment of Advanced Stage NK/T-cell Lymphoma
Ruijin Hospital
Phase 2 Unknown
NCT03991559 2019-08-28
A Safety Study of the Pan-immunotherapy in Patients With Unresectable/Metastatic Solid Tumors or Lymphomas
Chinese PLA General Hospital
Phase 1 Unknown